Vivoryon Therapeutics N.V. buy melinda
Start price
26.11.17
/
50%
€11.80
Target price
16.01.18
€17.00
Performance (%)
23.74%
End price
16.01.18
€14.60
Summary
This prediction ended on 16.01.18 with a price of €14.60. The prediction had a final performance of 23.74%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Vivoryon Therapeutics N.V. | -6.527% | -6.527% | -82.775% | -90.475% |
iShares Core DAX® | -2.385% | 3.986% | 16.836% | 16.377% |
iShares Nasdaq 100 | -4.527% | -0.258% | 18.824% | 29.987% |
iShares Nikkei 225® | -4.129% | 4.382% | 10.912% | -1.507% |
iShares S&P 500 | -2.885% | 1.387% | 20.391% | 35.258% |
According to melinda what are the pros and cons of Vivoryon Therapeutics N.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Vivoryon Therapeutics AG diskutieren
Biotechnologie und Medizintechnik SecteurRecherche Agenda 27/11 | 02.00 Präsentation
Probiodrug ist auf die Erforschung und Entwicklung von therapeutischen Produkten für die Behandlung der Alzheimer-Krankheit. Am Ende 2016 hat die Gruppe einen Portfolio von Produkten 2 in der vorklinischen Entwicklung (PBD-C06 und PQ1565) und ein Produkt in der Phase IIa
(Vom Mitglied beendet)
Stopped prediction by melinda for Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€18.36
27.11.21
27.11.21
€19.00
27.11.22
27.11.22
-50.44%
28.11.22
28.11.22
Could be worthwhile Investment >10% per year
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€3.80
16.03.20
16.03.20
€5.00
04.11.21
04.11.21
437.55%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€5.48
26.02.20
26.02.20
€7.50
16.03.20
16.03.20
-30.75%
16.03.20
16.03.20
Could be worthwhile Investment >10% per year
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€11.80
26.11.17
26.11.17
€17.00
16.01.18
16.01.18
23.74%
16.01.18
16.01.18
Could be worthwhile Investment >10% per year